ReviewFrontiers in immunology2025
Crosstalk between stromal, immune, and ovarian cancer cells in lipid-rich tumor microenvironment exhibits proliferative features.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies.Cancers · 2026Review
- Unveiling the Dual Mechanisms ofInternational journal of molecular sciences · 2026Article
- Global research trends and hotspots of plant physiologically active substances: quantitative visualization analysis based on CiteSpace.Plant biology (Stuttgart, Germany) · 2026Article
- KLF5-driven TAZ-FASN signaling reprograms fatty acid metabolism to support Treg differentiation in lung cancer.Journal of translational medicine · 2026Article
- Immune heterogeneity and therapeutic resistance in gynecological malignancies.Frontiers in immunology · 2026Review
- Central Roles of Glucosylceramide in Driving Cancer Pathogenesis.International journal of molecular sciences · 2025Review
- TGF-β-driven T-cell exclusion in ovarian cancer: single-cell and spatial transcriptomic views of immune low-response states.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid metabolism reprogramming has long been noticed as the hallmark of ovarian cancer, in order to maintain proliferative features including rapid cell division, metastasis capability, and chemotherapy resistance, as well as to survive under environmental stress, alteration of lipid metabolic pathways takes place, especially over-expression of rate-limiting enzymes, enhances lipid uptake, fatty acid synthesis, β-oxidation, lipid storage, and cellular membrane construction. In lipid-rich ascites and omental tumor microenvironments, the biological functions of stromal and immune cells change, forming a premetastatic niche and immunosuppressive tumor microenvironment via modifying extracellular matrix components and secreting cytokines. The crosstalk between stromal, immune, and ovarian cancer cells results in tumor proliferation, metastasis, and escape of immune surveillance. Given the importance of lipid metabolism for ovarian cancer survival, targeting lipid metabolism key enzymes in ovarian cancer or stromal tumor microenvironment may bring novel insights for ovarian cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.